In the CATT (Comparison of Age-related Macular Degeneration Treatment Trials), the primary finding regarding ranibizumab versus bevacizumab for neovascular AMD after 2 years was:
- A Ranibizumab was significantly superior in visual acuity gain
- B Visual acuity outcomes were equivalent but bevacizumab had higher serious systemic adverse event rates ✓
- C Bevacizumab showed significantly higher rates of systemic adverse events
- D Monthly dosing was equivalent to as-needed dosing for both drugs
Correct answer: B. Visual acuity outcomes were equivalent but bevacizumab had higher serious systemic adverse event rates
Explanation
The CATT trial showed that ranibizumab and bevacizumab were equivalent in mean visual acuity outcomes at 2 years. However, bevacizumab was associated with a higher rate of serious systemic adverse events (primarily hospitalizations, though no single category reached significance alone). Additionally, monthly dosing was superior to as-needed (PRN) dosing for both drugs in anatomic outcomes (reduction of subretinal fluid), though VA outcomes were similar between monthly and PRN regimens.
Reference: Khurana Comprehensive Ophthalmology, 7th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.